Home > Rheumatology > EULAR 2019 > Psoriatic Arthritis > Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Presented By
Dr Amanda Gellett, Eli Lilly, USA
EULAR 2019
Phase 3, SPIRIT-P2
Data from a post-hoc analysis show that use of ixekizumab improves signs and symptoms of difficult-to-treat psoriatic arthritis (PsA) patients who previously failed to respond to 1 or 2 TNF inhibitor (TNFi) therapies. “PsA is a progressive, chronic inflammatory disease that is often treated with TNFi when conventional treatments have failed. We have learned from rheumatoid arthritis (RA) and PsA that patients with an inadequate response to the first TNFi generally have a decreased response to subsequent TNFi,” said Dr Amanda Gellett (Eli Lilly, USA). In addition, in a substantial proportion of patients, TNFi therapy might be contra-indicated or not tolerated. “Also, nearly 40% of the patients in this population switched TNFis as part of their routine care, and that was mainly due to lack of efficacy,” added Dr Gellett. Therefore, therapies with an alternative mechanism of action in PsA are clinically important. The anti–interleukin-17 drug ixekizuma...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on